Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
How management deployed cash over 6 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Insufficient data. Current ROIC on all capital: 10%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 6 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.” Effective rate ~4.6% on $13.4B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-14
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $32.05B 100.0% | $26.11B 100.0% | $32.64B 100.0% | $10.97B 100.0% | $5.95B 100.0% | $2.35B 100.0% |
| Total Operating Expenses | $25.29B 78.9% | $18.98B 72.7% | $27.33B 83.7% | $15.91B 145.1% | $4.11B 69.1% | $1.58B 67.1% |
| Interest Expense | $618.0M 1.9% | $474.0M 1.8% | $268.0M 0.8% | $222.0M 2.0% | $138.0M 2.3% | $133.0M 5.6% |
| Pretax Income | $6.68B 20.8% | $7.43B 28.5% | $5.59B 17.1% | -$4.25B -38.7% | $4.86B 81.7% | $553.0M 23.5% |
| Income Tax Expense | $1.28B 4.0% | $1.06B 4.1% | -$923.0M -2.8% | -$739.0M -6.7% | $594.0M 10.0% | $86.0M 3.7% |
| Net Income | $3.40B 10.6% | $4.48B 17.2% | $5.00B 15.3% | -$1.96B -17.9% | $1.80B 30.3% | $157.0M 6.7% |
| Per Share | ||||||
| EPS (Basic) | $5.58 | $7.39 | $8.32 | $-3.43 | $7.32 | $0.44 |
| EPS (Diluted) | $5.54 | $7.33 | $8.28 | $-3.43 | $7.32 | $0.44 |
| Weighted Avg Shares (Basic) | 589.5M | 586.1M | 581.4M | 584.7M | 236.6M | 227.5M |
| Weighted Avg Shares (Diluted) | 593.7M | 604.0M | 588.8M | 584.7M | 236.6M | 227.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $1.2B dividends + $773M buybacks = $2.0B returned.
3 consecutive years of dividend increases · -3%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-14
No material risks flagged.
Where each multiple sits in its own 6-yr range · 31th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax | 3.7 | 10.0 | -6.7 | -2.8 | 4.1 | 4.0 |
| Net Income | 6.7 | 30.3 | -17.9 | 15.3 | 17.2 | 10.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on APO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.